Nov 4 (Reuters) - Sino Biopharmaceutical 1177.HK said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.
Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk
